NCT07217496 2026-03-17N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerUniversity of California, San FranciscoPhase 1 Withdrawn
NCT04290546 2026-02-27CIML NK Cell in Head & Neck CancerDana-Farber Cancer InstitutePhase 1 Completed11 enrolled